Acute Leukemias - Republican Scientific Medical Library

More documents

Recommendations

Info

a References 235 mine the best pretransplant conditioning regimen and purging methods to decrease disease burden. In addition, further studies are required to determine the benefit of maintenance therapy posttransplant to decrease the rate of disease relapse. Finally, immunologic therapies currently under preclinical investigation may provide an effective alternative to the GVL phenomenon, and improve the outcome with autologous SCT in future trials. References 1. Kantarjian HM, et al. (2000) Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18(3):547–561 2. Larson RA (2000) Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. Hematol Oncol Clin North Am 14(6):1367–1379 3. Linker C, et al. (2002) Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol 20(10):2464–2471 4. Hoelzer D, et al. (1988) Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 71(1):123–131 5. Wetzler M, et al. (1999) Prospective karyotype analysis in adult acute lymphoblastic leukemia: The cancer and leukemia Group B experience. Blood 93(11):3983–3993 6. Wetzler M (2000) Cytogenetics in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am 14(6):1237–1249 7. Horowitz MM, et al. (1991) Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. Ann Intern Med 115(1):13–18 8. Thiebaut A, et al. (2000) Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am 14(6):1353–1366 9. Rowe J (2001) Favorable results of allogeneic bone marrow transplantation (BMT) for adults with Philadelphia (Ph)-chromosomenegative acute lymphoblastic leukemia (ALL) in first complete remission (CR): Results from the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 98:2009a 10. Doney K, et al. (1993) Autologous bone marrow transplantation for acute lymphoblastic leukemia. Bone Marrow Transplant 12(4):315–321 11. Abdallah A, et al. (2001) Continuous complete remission in adult patients with acute lymphocytic leukaemia at a median observation of 12 years after autologous bone marrow transplantation. Br J Haematol 112(4):1012–1015 12. Uckun FM, et al. (1992) Autologous bone marrow transplantation in high-risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3/CD10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo bone marrow purging. Blood 79(4):1094–1104 13. Singhal S, et al. (2003) Haploidentical vs. autologous hematopoietic stem cell transplantation in patients with acute leukemia beyond first remission. Bone Marrow Transplant 31(10):889–895 14. Sebban C, et al. (1994) Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: A comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol 12(12):2580–2587 15. Weisdorf DJ, et al. (1997) Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia. Blood 90(8):2962–2968 16. Ringden O, et al. (1997) Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis. Acute Leukaemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation (EBMT) and the International Marrow Unrelated Search and Transplant (IMUST) Study. Bone Marrow Transplant 19(10):963– 968 17. Powles R, et al. (2000) Allogeneic blood and bone-marrow stemcell transplantation in haematological malignant diseases: A randomised trial. Lancet 355(9211):1231–1237 18. Atta J, et al. (2000) Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: Comparison of residual leukemia and purging efficiency in bone marrow vs. peripheral blood stem cells by semiquantitative polymerase chain reaction. Bone Marrow Transplant 25(1):97–104 19. van Rhee F, et al. (1995) Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: Comparison of blood and bone marrow. Leukemia 9(2):329–335 20. Sutton L, et al. (1993) Allogeneic bone marrow transplantation for adult acute lymphoblastic leukemia in first complete remission: Factors predictive of transplant-related mortality and influence of total body irradiation modalities. Bone Marrow Transplant 12(6):583–589 21. Blume KG, et al. (1987) Total body irradiation and high-dose etoposide: A new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 69(4):1015–1020 22. Carey PJ, et al. (1991) Autologous bone marrow transplantation for high-grade lymphoid malignancy using melphalan/irradiation conditioning without marrow purging or cryopreservation. The Northern Regional Bone Marrow Transplant Group. Blood 77(7): 1593–1598 23. Kersey JH, et al. (1987) Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. N Engl J Med 317(8):461–467 24. Woods WG, et al. (1990) Bone marrow transplantation for acute lymphocytic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside: Lack of superiority over cyclophosphamide-containing conditioning regimens. Bone Marrow Transplant 6(1):9–16 25. Billett AL, et al. (1993) Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia. Blood 81(6):1651–1657 26. Maldonado MS, et al. (1998) Autologous bone marrow transplantation with monoclonal antibody purged marrow for children with acute lymphoblastic leukemia in second remission. Spanish Working Party for BMT in Children. Bone Marrow Transplant 22(11):1043–1047
236 Chapter 18 · The Role of Autologous Stem Cell Transplantation in the Management of Acute Lymphoblastic Leukemia in Adults 27. Soiffer RJ, et al. (1993) Monoclonal antibody-purged autologous bone marrow transplantation in adults with acute lymphoblastic leukemia at high risk of relapse. Bone Marrow Transplant 12(3): 243–251 28. Flinn IW, Lazarus HM (2001) Monoclonal antibodies and autologous stem cell transplantation for lymphoma. Bone Marrow Transplant 27(6):565–569 29. Buchmann I, et al. (2002) Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: Biodistribution, biokinetics and immediate toxicities. Cancer Biother Radiopharm 17(2):151–163 30. Blume KG, et al. (1993) A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: A Southwest Oncology Group study. Blood 81(8):2187–2193 31. Copelan EA, Deeg HJ (1992) Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation. Blood 80(7):1648– 1658 32. Rowley SD, et al. (1987) CFU-GM content of bone marrow graft correlates with time to hematologic reconstitution following autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide-purged bone marrow. Blood 70(1):271–275 33. Douay L, et al. (1995) Amifostine improves the antileukemic therapeutic index of mafosfamide: Implications for bone marrow purging. Blood 86(7):2849–2855 34. Hatta Y, et al. (2002) Purging in autologous hematopoietic stem cell transplantation using adenosine triphosphate (ATP) and 4-hydroperoxycyclophosphamide (4-HC). Leuk Res 26(5):477–482 35. Preijers FW, et al. (1989) Autologous transplantation of bone marrow purged in vitro with anti-CD7-(WT1-) ricin A immunotoxin in T-cell lymphoblastic leukemia and lymphoma. Blood 74(3):1152– 1158 36. Gilmore MJ, et al. (1991) Failure of purged autologous bone marrow transplantation in high risk acute lymphoblastic leukaemia in first complete remission. Bone Marrow Transplant 8(1): 19–26 37. Granena A, et al. (1999) Autologous bone marrow transplantation for high risk acute lymphoblastic leukemia: Clinical relevance of ex vivo bone marrow purging with monoclonal antibodies and complement. Bone Marrow Transplant 24(6):621–627 38. Morishima Y, et al. (1993) Autologous BMT in high risk patients with CALLA-positive ALL: Possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement. Bone Marrow Transplant 11(4):255–259 39. Canals C, et al. (1997) Immunomagnetic bone marrow purging in children with acute lymphoblastic leukemia. J Hematother 6(3): 261–268 40. Mehta J, et al. (1997) Autologous transplantation with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia: Long-term follow-up. Leuk Lymphoma 25(5–6):479– 486 41. Luger SM, et al. (2002) Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: A pilot study. Blood 99(4):1150–1158 42. Powles R, et al. (2002) The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia. Blood 100(5):1641– 1647 43. Druker BJ, et al. (2001) Activity of a specific inhibitor of the BCR- ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344(14):1038–1042 44. Avivi I, Goldstone AH (2003) Bone marrow transplant in Ph+ ALL patients. Bone Marrow Transplant 31(8):623–632 45. Blaise D, et al. (2000) Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission. Eur Cytokine Netw 11(1):91–98 46. de Rijke B, et al. (2003) Generation of autologous cytotoxic and helper T-cell responses against the B-cell leukemia-associated antigen HB-1: Relevance for precursor B-ALL-specific immunotherapy. Blood 102(8):2885–2891
Page 1 and 2:
E.H. Estey · S.H. Faderl · H. M.
Page 3 and 4:
E. H. Estey Department of Leukemia
Page 5 and 6:
VI Table of Contents 14 Philadelphi
Page 7 and 8:
VIII Contributors S. H. Faderl Depa
Page 9 and 10:
X Contributors D. Wartenberg Depart
Page 11 and 12:
Therapy of AML Elihu Estey Contents
Page 13 and 14:
a 1.2 · Standard Therapy 3 Table 1
Page 15 and 16:
a 1.2 · Standard Therapy 5 Table 1
Page 17 and 18:
a 1.2 · Standard Therapy 7 tween G
Page 19 and 20:
a 1.2 · Standard Therapy 9 Fig. 1.
Page 21 and 22:
a 1.2 · Standard Therapy 11 of tre
Page 23 and 24:
a 1.2 · Standard Therapy 13 Table
Page 25 and 26:
a 1.2 · Standard Therapy 15 permit
Page 27 and 28:
a References 17 19. Care RS, Valk P
Page 29 and 30:
a References 19 6-thioguanine in th
Page 31 and 32:
Acute Myeloid Leukemia: Epidemiolog
Page 33 and 34:
a 3.1 · Epidemiology 49 3.1.4 Gend
Page 35 and 36:
a 3.2 · Etiology 51 part of the in
Page 37 and 38:
a 3.2 · Etiology 53 for the develo
Page 39 and 40:
a References 55 38. Crane MM, Stom
Page 41 and 42:
Relapsed and Refractory Acute Myelo
Page 43 and 44:
a 4.2 · Prognostic Factors in Pati
Page 45 and 46:
a 4.3 · Treatment of Relapsed and
Page 47 and 48:
a 4.4 · Hematopoietic Stem Cell Tr
Page 49 and 50:
a 4.6 · Gemtuzumab Ozogamicin 65 T
Page 51 and 52:
a 4.7 · Relapsed and Refractory Ac
Page 53 and 54:
a 4.7 · Relapsed and Refractory Ac
Page 55 and 56:
a References 71 The ability of immu
Page 57 and 58:
a References 73 39. Vogler WR, McCa
Page 59 and 60:
a References 75 95. Sievers EL, Lar
Page 61 and 62:
Part II - Acute Lymphoblastic Leuke
Page 63 and 64:
78 Chapter 5 · Acute Lymphoblastic
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Molecular Biology and Genetics Meir
Page 81 and 82:
a 6.3 · Structural Aberrations 97
Page 83 and 84:
a 6.3 · Structural Aberrations 99
Page 85 and 86:
a 6.5 · Molecular Aberrations 101
Page 87 and 88:
a References 103 clear that homozyg
Page 89 and 90:
a References 105 53. Chim CS, Tam C
Page 91 and 92:
a References 107 122. Lennard L, Li
Page 93 and 94:
Diagnosis of Acute Lymphoblastic Le
Page 95 and 96:
a 8.3 · Cytochemistry and Immunoph
Page 97 and 98:
a 8.5 · Cytogenetic and Molecular
Page 99 and 100:
a 8.5 · Cytogenetic and Molecular
Page 101 and 102:
a References 127 including the reti
Page 103 and 104:
a References 129 47. Kita K, Shirak
Page 105 and 106:
Acute Lymphoblastic Leukemia: Clini
Page 107 and 108:
a 7.3 · Diagnosis 111 or neoplasti
Page 109 and 110:
a 7.3 · Diagnosis 113 Fig. 7.2. Hi
Page 111 and 112:
a 7.3 · Diagnosis 115 The vast maj
Page 113 and 114:
a References 117 dren: Biologic bas
Page 115 and 116:
General Approach to the Therapy of
Page 117 and 118:
a 9.3 · New Agents 133 dose methot
Page 119 and 120:
a References 135 4. Gökbuget N, Ho
Page 121 and 122:
138 Chapter 10 · Recent Clinical T
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
146 Chapter 11 · Conventional Ther
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
ALL Therapy: Review of the MD Ander
Page 145 and 146:
a 12.2 · The Hyper-CVAD Regimen in
Page 147 and 148:
a 12.3 · Subset-Specific Approache
Page 149 and 150:
Treatment of Adult ALL According to
Page 151 and 152:
a 13.2 · Therapy for Younger (15-6
Page 153 and 154:
a 13.3 · Therapy of Ph/BCR-ABL-Pos
Page 155 and 156:
a 13.5 · Prognostic Factors 173 13
Page 157 and 158:
a References 175 Only patients with
Page 159 and 160:
Philadelphia Chromosome-Positive Ac
Page 161 and 162:
a 14.2 · Molecular Biology of the
Page 163 and 164:
a 14.3 · Treatment of Ph+ ALL 181
Page 165 and 166: a 14.4 · Hematopoietic Stem Cell T
Page 167 and 168: a References 185 2. Kurzrock R, Sht
Page 169 and 170: a References 187 56. Mori T, Manabe
Page 171 and 172: a References 189 acute lymphoblasti
Page 173 and 174: 192 Chapter 15 · Burkitt’s Acute
Page 185 and 186: 204 Chapter 16 · Treatment of Lymp
Page 197 and 198: 216 Chapter 17 · The Role of Allog
Page 211 and 212: 230 Chapter 18 · The Role of Autol
Page 213 and 214: 232 Chapter 18 · The Role of Autol
Page 215: 234 Chapter 18 · The Role of Autol
Page 219 and 220: 238 Chapter 19 · Novel Therapies i
Page 229 and 230: 248 Chapter 20 · Minimal Residual
Page 245 and 246: 264 Chapter 21 · Central Nervous S
Page 257 and 258: 276 Chapter 22 · Relapsed Acute Ly
Page 259 and 260: 278 Chapter 22 · Relapsed Acute Ly
Page 261 and 262: Emergencies in Acute Lymphoblastic
Page 263 and 264: a 23.5 · Hyperleukocytosis 283 LA
Page 265 and 266: a 23.9 · Neurological Complication
Page 267 and 268:
a References 287 29. Hingorani AD,
Page 269 and 270:
Subject Index A aberrant methylatio
Page 271 and 272:
a Subject Index 291 CREB, see enhan
Page 273 and 274:
a Subject Index 293 MUD, see matche
show all

Acute Leukemias - Republican Scientific Medical Library

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?